BEF, Author at The Boomer Esiason Foundation

March 19, 2019

SOURCE In the 1980s, life expectancy for persons with cystic fibrosis (CF) was just 12 years in the US, and around 20 in Canada. However, the median age of survival for Canadian CF patients continues on an upward trend, and is currently estimated to be 50.9...

UNC Researchers Find New CF Drugs Counteract One Another’s Effectiveness via CF News Today

by BEF

CF News, Research, Therapies

March 19, 2019

SOURCE Findings of new study led by Martina Gentzsch, PhD, at the University of North Carolina School of Medicine and the UNC Marsico Lung Institute in Chapel Hill, N.C. could help drug developers improve compounds designed to correct CFTR proteins in cystic fibrosis (CF) patients. In...

Vertex’s Two-Drug Cystic Fibrosis Treatment Shows Promise in Clinical Trials via NY Times

by BEF

CF News, Research, Therapies

March 19, 2019

Vertex Pharmaceuticals said on Tuesday that a combination of two of its drugs had successfully treated cystic fibrosis in closely watched clinical trials, potentially clearing the way for approval of a new option for nearly half the patients with the genetic disease. The drug combination, when...

Vertex Announces Presentation of New KALYDECO™ (ivacaftor) Data via Market Watch

by BEF

CF News, Research

March 19, 2019

Via Source: Marketwatch.com New data showed that KALYDECO reduced the loss of lung function by half over 3 years in people with CF who have the G551D mutation compared to similar untreated patients--New data from rollover study of ivacaftor in people with the R117H mutation support...

Aptalis Pharma Studies Panzytrat in Cystic Fibrosis Patients in Phase 4 Trial via CF News Today

by BEF

CF News, Research, Therapies

March 19, 2019

via Cystic Fibrosis News Today Aptalis Pharma continued to evaluate its pancreatic enzyme products (PEPs) in patients with cystic fibrosis and exocrine pancreatic insufficiency in its Phase 4 clinical trial of Panzytrat® 25,000. Results show that patients taking Panzytrat had better control over their steatorrhea, or...

Pancreatic Enzyme Products May Benefit Cystic Fibrosis Patients with Malabsorption via CF News Today

by BEF

CF News, Research, Therapies

March 19, 2019

Via Cystic Fibrosis News Today After the Food and Drug Administration (FDA) issued rules requiring approval of pancreatic enzyme products (PEPs) in 2004, the cost and availability of the products added another hardship to the lives of cystic fibrosis patients, some of whom use PEPs to...

IFN-γ Found to Help Clear Lethal Bacteria in Cystic Fibrosis Infections via Bio News -TX

by BEF

CF News, Research, Therapies

March 19, 2019

SOURCE - BIO NEWS TEXAS Researchers at The Research Institute at Nationwide Children’s Hospital in Ohio are finding ways to boost immunity in cystic fibrosis patients. Colleagues in principal investigator Dr. Benjamin Kopp’s laboratory published a study in PLoS One that details the use of interferon...

Alcresta Announces Agreement with CFF Therapeutics to Develop Point-of-Care Nutritional Products

by BEF

CF Community, CF News, Research, Therapies

March 19, 2019

SOURCE - Marketwatch.com PRESS RELEASE April 17, 2014, 7:31 a.m. EDT Alcresta Announces Agreement with Cystic Fibrosis Foundation Therapeutics to Develop Point-of-Care Nutritional Products Agreement Highlights Importance of Medical Nutrition in Managing Cystic Fibrosis NEWTON, Mass., Apr 17, 2014 (BUSINESS WIRE) -- Alcresta®, a leading medical nutrition company developing innovative...

Attention CF Patients with Persistent MRSA Lung Infection

by BEF

CF Community, CF News, Research

March 19, 2019

Attention CF Patients With Persistent MRSA Lung Infection: A Phase 2 clinical trial to evaluate the safety and efficacy of an inhaled anti-MRSA antibiotic is enrolling now. MRSA + CF The prevalence of MRSA lung infection in cystic fibrosis (CF) patients has risen in the past decade, currently...

Kamada Ltd. Launching New CF Clinical Trial this Summer

by BEF

CF Community, CF News, Research, Therapies

March 19, 2019

SOURCE [Posted by Mike Nace on bionews-tx.com] Israel-based Kamada Ltd., a drug development company currently developing plasma-derived protein therapeutics that are chiefly targeting orphan diseases, indicated recently in a press release that their lead drug candidate Alpha-1 Antitrypsin (AAT), which is currently in trials for treatment of...

Author: BEF

Median Age Of Survival For Canadians With CF Surpasses 50 via CF News Today

UNC Researchers Find New CF Drugs Counteract One Another’s Effectiveness via CF News Today

Vertex’s Two-Drug Cystic Fibrosis Treatment Shows Promise in Clinical Trials via NY Times

Vertex Announces Presentation of New KALYDECO™ (ivacaftor) Data via Market Watch

Aptalis Pharma Studies Panzytrat in Cystic Fibrosis Patients in Phase 4 Trial via CF News Today

Pancreatic Enzyme Products May Benefit Cystic Fibrosis Patients with Malabsorption via CF News Today

IFN-γ Found to Help Clear Lethal Bacteria in Cystic Fibrosis Infections via Bio News -TX

Alcresta Announces Agreement with CFF Therapeutics to Develop Point-of-Care Nutritional Products

Attention CF Patients with Persistent MRSA Lung Infection

Kamada Ltd. Launching New CF Clinical Trial this Summer

Never miss an update. Subscribe to our emails!